Tee Yi-Torng, Wang Po-Hui, Yang Shun-Fa, Tsai Hsiu-Ting, Lee Shu-Kuei, Ko Jiunn-Liang, Lin Long-Yau, Chen Shiuan-Chih
Institute of Medicine, Chung Shan Medical University, 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan; Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital, 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan; School of Medicine, Chung Shan Medical University, 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan.
Institute of Medicine, Chung Shan Medical University, 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan; Department of Medical Research, Chung Shan Medical University Hospital, 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan; Department of Clinical Laboratory, Chung Shan Medical University Hospital, 110, Section 1, Chien-Kuo North Road, Taichung 40201, Taiwan.
Taiwan J Obstet Gynecol. 2014 Jun;53(2):158-61. doi: 10.1016/j.tjog.2014.04.006.
To investigate the correlation of two important inflammatory biomarkers, plasma osteopontin and neutrophil gelatinase-associated lipocalin (NGAL), with the severity and outcome of pelvic inflammatory disease (PID).
Sixty-one patients with PID, including 25 patients with tubo-ovarian abscess (TOA), were consecutively recruited. Their blood samples were tested for the concentrations of plasma osteopontin and NGAL using enzyme-linked immunosorbent assay. The associations of these biomarkers with TOA, length of hospitalization, and incidence of surgery were also analyzed.
Plasma osteopontin level was significantly increased in PID patients with TOA compared to PID patients without TOA (median 107.77 ng/mL vs. 72.39 ng/mL, p = 0.004). However, there was no significant difference for plasma NGAL. If the cutoff level of plasma osteopontin was set at 81.1 ng/mL, there was a 76.0% sensitivity and a 24.0% false negative rate in predicting TOA in PID patients. Plasma osteopontin significantly correlated with length of hospital stay (r = 0.467, p < 0.001), and this correlation was better than that of NGAL. However, neither biomarker was associated with incidence of surgery.
Plasma osteopontin has a better correlation with TOA and length of hospitalization compared to NGAL. If plasma osteopontin level falls below 81.1 ng/mL, PID patients will have about a 20% chance of developing TOA. Incorporating plasma osteopontin, but not NGAL, will allow for an adjuvant diagnostic biomarker for TOA and predictor of length of hospital stay.
探讨两种重要的炎症生物标志物——血浆骨桥蛋白和中性粒细胞明胶酶相关脂质运载蛋白（NGAL）与盆腔炎性疾病（PID）严重程度及预后的相关性。
连续纳入61例PID患者，其中包括25例输卵管卵巢脓肿（TOA）患者。采用酶联免疫吸附测定法检测其血样中血浆骨桥蛋白和NGAL的浓度。还分析了这些生物标志物与TOA、住院时间及手术发生率的相关性。
与无TOA的PID患者相比，有TOA的PID患者血浆骨桥蛋白水平显著升高（中位数分别为107.77 ng/mL和72.39 ng/mL，p = 0.004）。然而，血浆NGAL水平无显著差异。若将血浆骨桥蛋白的临界值设定为81.1 ng/mL，则预测PID患者发生TOA的灵敏度为76.0%，假阴性率为24.0%。血浆骨桥蛋白与住院时间显著相关（r = 0.467，p < 0.001），且这种相关性优于NGAL。然而，两种生物标志物均与手术发生率无关。
与NGAL相比，血浆骨桥蛋白与TOA及住院时间的相关性更好。若血浆骨桥蛋白水平低于81.1 ng/mL，PID患者发生TOA的几率约为20%。纳入血浆骨桥蛋白而非NGAL，可作为TOA的辅助诊断生物标志物及住院时间的预测指标。
